MedSwitcher

Health & Medication Blog

Evidence-based guides, comparisons, and practical advice for GLP-1 medications, TRT, HRT, mental health, and more. Updated regularly with the latest research, FDA news, and pricing.

Showing 11 articlesin New MedicationsClear filters
New Medications11 min read

Wegovy HD 7.2mg: Everything You Need to Know About the New High Dose

Novo Nordisk's Wegovy HD brings semaglutide to 7.2mg — tripling the original dose. The STEP UP trial shows it closing the gap with Zepbound on weight loss. Here's the full breakdown.

Apr 4, 2026Read article →
New Medications8 min read

Using Foundayo for Weight Maintenance After Zepbound: Lilly's Strategy Explained

Eli Lilly did not create Foundayo by accident. The oral GLP-1 pill is the second half of a deliberate two-product strategy: lose aggressively with Zepbound, then maintain conveniently with Foundayo. Here is how the playbook works and whether it makes sense for you.

Apr 9, 2026Read article →
New Medications8 min read

GLP-1 Medications for PCOS Weight Loss: What the Research Shows

PCOS makes weight loss harder. Here's what the research says about using GLP-1 medications like Foundayo, Ozempic, and Zepbound for PCOS.

Apr 9, 2026Read article →
New Medications7 min read

Foundayo Weight Loss Timeline: What to Expect Month by Month

Here's exactly what to expect from Foundayo — from your first 0.8mg pill through reaching the maximum dose, month by month.

Apr 9, 2026Read article →
New Medications10 min read

CagriSema: Everything You Need to Know About Novo Nordisk's Next Weight Loss Drug

CagriSema pairs semaglutide with the amylin analog cagrilintide for 22.7% weight loss in trials — rivaling Zepbound. Here's everything we know ahead of the expected October 2026 FDA decision.

Apr 9, 2026Read article →
New Medications9 min read

Retatrutide: Lilly's Triple Agonist With 28.7% Weight Loss — What We Know

Retatrutide hit 28.7% weight loss in Phase 2 — the most ever recorded in an obesity trial. Lilly's triple agonist is now in Phase 3, with approval possible by 2027-2028.

Apr 9, 2026Read article →
New Medications12 min read

GLP-1 Drug Pipeline 2026-2027: Every New Weight Loss Medication Coming Next

At least six major obesity drugs are in Phase 2-3 trials right now. Here's every GLP-1 and incretin medication in the pipeline for 2026 and 2027.

Apr 9, 2026Read article →
New Medications7 min read

Foundayo Real Results: What Patients Are Reporting in the First Week

Foundayo has been available for just days since its April 6 launch. Here's what early patients are saying so far — and what you should realistically expect in week one.

Apr 9, 2026Read article →
New Medications7 min read

How to Get Foundayo in 2026: Prescription, Pricing & Where to Buy

Foundayo is FDA-approved and shipping now. Here's exactly how to get it — LillyDirect, Amazon Pharmacy, telehealth, insurance, and every way to save.

Apr 10, 2026Read article →
New Medications8 min read

Can You Use Foundayo for Type 2 Diabetes? What We Know About Orforglipron and Blood Sugar

Foundayo is FDA-approved for weight loss, not diabetes — yet. But ATTAIN-2 trial data shows a 1.6% A1C reduction. Here is what the science says and when the diabetes approval might come.

Apr 10, 2026Read article →
New Medications13 min read

Awiqli vs Daily Insulin: Is Once-Weekly Insulin Right for You?

Awiqli is the first once-weekly insulin, offering 52 injections per year instead of 365. But is it as effective as daily Lantus or Tresiba? Here is the complete comparison for type 2 diabetes patients.

Apr 9, 2026Read article →

Planning a medication switch?

Use our free calculator to get a personalized switching plan, dose mapping, and cost comparison.

Try the MedSwitcher Calculator

Research without missing the move

Get the important GLP-1 updates, not more noise

We’ll send the high-signal stuff only: pricing changes, shortages, and new switch guidance worth acting on.

  • Price and access changes
  • New medication comparisons
  • Actionable switch guidance

No spam. Unsubscribe anytime. We never share your email.